Actively Recruiting
Retrospective Analysis of the Effect of In-hospital Initiation of PCSK9i on Clinical Outcomes in Chinese ACS Patients
Led by Yun Dai Chen · Updated on 2024-08-22
10000
Participants Needed
1
Research Sites
26 weeks
Total Duration
On this page
Sponsors
Y
Yun Dai Chen
Lead Sponsor
S
Sanofi
Collaborating Sponsor
AI-Summary
What this Trial Is About
The objective of this study is to investigate the effectiveness of in-hospital initiation of alirocumab combined with statin ± ezetimibe on major cardiovascular events (MACE) in Chinese ACS patients. The main question it aims to answer is: whether early initiation PCKS9i in hospital could reduce recent cardiovascular event risk in Chinese ACS patients in real-world setting. Data from CCA Database-Chest Pain Center were screened for all ACS patients from 01-Jan 2021 to 31-Dec 2023. Patients diagnosed with STEMI, NSTEMI or UA at admission were identified at the first step. Then, for intervention group, patients who received alirocumab 75mg combined with statin ± ezetimibe during the ACS hospitalization (including the discharge date) will be included; for control group, patients who received statin ± ezetimibe during the ACS hospitalization will be included. All enrolled patients were required to have at least one documented follow-up visit.
CONDITIONS
Official Title
Retrospective Analysis of the Effect of In-hospital Initiation of PCSK9i on Clinical Outcomes in Chinese ACS Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with Acute Coronary Syndrome (ACS) upon hospital admission.
- Patients aged 18 years or older.
- Patients who received Alirocumab 75 mg in combination with statin therapy Ezetimibe as the intervention group, and those treated exclusively with statin therapy Ezetimibe as the control group, either during hospitalization or at discharge.
- Patients with at least one follow-up record.
You will not qualify if you...
- Patients who received Evolocumab treatment at any time.
- Patients who received Inclisiran treatment at any time.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chinese PLA General Hospital
Beijing, Beijing Municipality, China, 100853
Actively Recruiting
Research Team
D
Dandan Li, Dr.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here